查看文章

Background

Current treatment for metastatic colorectal cancer (mCRC), includes anti-epidermal growth factor receptor inhibitors (EGFRi) for RAS wildtype cancers. With improved outcomes has come added complexity for clinician treatment selection and sequencing. Head-to-head studies support first-line EGFRi use over bevacizumab in combination with chemotherapy for patients with a left-side primary. In January 2015, the EGFRi cetuximab gained government approval for first-line use in Australia, with routine RAS testing increasing in turn. In clinical practice, around 50% of patients do not receive second-line treatment, suggesting many patients miss out on this treatment option if reserved for second-line and later treatment.

Methods

Clinical data from July 2009 to July 2021 was reviewed from TRACC (Treatment of Recurrent and Advanced Colorectal Cancer), a prospective, comprehensive, multi-site …